Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of an Anti-LILRB2 / PD-L1 Bispecific Antibody SPX- 303 in Patients With Solid Tumors

NCT06259552 is registered in ClinicalTrials.gov with SparX Biotech(Jiangsu) Co., Ltd. as lead sponsor.

NCT NCT06259552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06259552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of an Anti-LILRB2 / PD-L1 Bispecific Antibody SPX- 303 in Patients With Solid Tumors
Lead sponsor
SparX Biotech(Jiangsu) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 20, 2024
Completion date
September 30, 2027
Enrollment
232 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

crc, hnscc, rcc, solid tumor